Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Igor Lokot | 9,01 | 16,06 | 2024-12-23 |
| KSDR Hamberg AB | 7,82 | 7,21 | 2024-12-23 |
| Per Ahlström | 7,74 | 7,14 | 2024-12-23 |
| Carl Carvalho | 4,01 | 3,70 | 2024-12-23 |
| QQM Fund Management AB | 3,73 | 3,44 | 2024-12-31 |
| Lars-Åke Börje Flarke | 3,60 | 3,32 | 2024-12-23 |
| Investentia AB | 3,30 | 3,05 | 2024-12-23 |
| Avanza Pension | 2,73 | 2,52 | 2024-12-23 |
| Magnus Hamberg | 2,57 | 2,37 | 2024-12-23 |
| Thomas Trumstedt | 1,95 | 1,80 | 2024-12-23 |
2025-02-27 Bokslutskommuniké 2024
2025-05-23 Delårsrapport 2025-Q1
